GlobeNewswire by notified

Convocation of the 2023 Annual General Meeting of Shareholders and Proposed Resolutions

Share

THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING
OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014).

EINDHOVEN, Pays-Bas et LAUSANNE, Suisse, et BOSTON, MA, Etats-Unis, March 27, 2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD) (the Company), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, today has convened the 2023 Annual General Meeting of Shareholders (AGM), including the resolutions to be submitted for adoption at the AGM, which will be held in Amsterdam, the Netherlands, on May 8, 2023.

The resolutions, proposed by the Board, to be submitted for adoption at the AGM, are as follows:

  • Adoption of the Company’s statutory annual accounts for the financial year ended December 31, 2022, prepared in accordance with International Financial Reporting Standards (IFRS-EU). The 2022 statutory accounts were filed with the Netherlands Authority for the Financial Markets (AFM) on March 27, 2023, and are posted on the Company’s website in the Investors section (https://ir.onwd.com) and the AFM’s website (www.afm.nl).
  • Implementation of the compensation policy over the financial year 2022 (advisory non-binding voting item).
  • Release from liability of the members of the Board with respect to the performance of their duties during the financial year 2022.
  • Instruction to Ernst & Young Accountants LLP for the external audit of the Company's annual accounts for the financial year 2023.
  • The re-appointment of Dr. Grégoire Courtine as non-executive director of the Board for a four-year term expiring at the end of the 2027 AGM.
  • The appointment of Ms. Vivian Riefberg as non-executive director of the Board for a four-year term expiring at the end of the 2027 AGM.
  • The delegation of the authority of the board to issue ordinary shares and to grant rights to subscribe for ordinary shares in the capital of the Company for 10% of the Company's issued share capital and to limit or exclude pre-emptive rights in connection therewith.
  • The delegation of the authority of the board to issue ordinary shares and to grant rights to subscribe for ordinary shares in the capital of the Company for 50% of the Company's issued share capital and to limit or exclude pre-emptive rights in connection with a potential capital raise.
  • The authorization to the Board to acquire ordinary shares in the capital of the Company.

The record date for all shareholders to participate at the AGM will be April 10, 2023. The convening notice, the complete agenda, and all relevant detailed information concerning the 2023 AGM, as well as all related AGM materials, are available on the Company’s website in the financial information of the Investors section (Financial Information - ONWARD Medical N.V. (onwd.com)) and made available to shareholders in compliance with legal requirements as of March 27, 2023.

To learn more about ONWARD’s ARC Therapy and the company’s vision to restore movement, independence, and health in people with spinal cord injury, please visit ONWD.com.

About ONWARD Medical

ONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injuries. ONWARD’s work builds on more than a decade of basic science and preclinical research conducted at the world’s leading neuroscience laboratories. ONWARD’s ARC Therapy, which can be delivered by implantable (ARC-IM) or external (ARC-EX) systems, is designed to deliver targeted, programmed spinal cord stimulation to restore movement and other functions in people with spinal cord injury, ultimately improving their quality of life.

ONWARD has received eight Breakthrough Device Designations from the US FDA encompassing both ARC-IM and ARC-EX. ARC-EX is an external, non-invasive platform consisting of a stimulator and wireless programmer. Positive top-line data were reported in 2022 from the company’s first pivotal study, called Up-LIFT, evaluating the ability of transcutaneous ARC Therapy to improve upper extremity strength and function. The company is now preparing marketing approval submissions for the US and Europe. ARC-IM consists of an implantable pulse generator and lead placed near the spinal cord. The company completed the first-in-human use of the ARC-IM neurostimulator and reported positive interim clinical outcomes for ARC-IM Therapy for improved blood pressure regulation following SCI in 2022.

ONWARD is headquartered in Eindhoven, the Netherlands. It maintains a Science and Engineering Center in Lausanne, Switzerland, and has a growing US presence in Boston, Massachusetts. The company has an academic partnership with .NeuroRestore, a collaboration between EPFL, the Swiss Federal Institute of Technology in Lausanne, and Lausanne University Hospital (CHUV). For additional information about the company, please visit ONWD.com. To access our 2023 Financial Calendar, please visit IR.ONWD.com.

For Company Enquiries:

info@onwd.com

For Media Enquiries:

MC Services AG
US: Laurie Doyle, P: +1 339 832 0752
Europe: Dr. Johanna Kobler, Katja Arnold, Kaja Skorka P: +49 89 210 228 0
media@onwd.com

For Investor Enquiries:

investors@onwd.com

Disclaimer

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors’ current expectations and projections about future events. By their nature, forward-looking statements involve several risks, uncertainties, and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition, and technology, can cause actual events, performance, or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions, or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Equinor ASA: Tilbakekjøp av egne aksjer19.3.2024 08:00:00 CET | Pressemelding

Nedenfor følger informasjon om transaksjoner foretatt under første transje av Equinor ASAs (OSE:EQNR, NYSE:EQNR, CEUX:EQNRO, TQEX:EQNRO) tilbakekjøpsprogram for 2024. Dato for når første transje av 2024-programmet ble annonsert: 7. februar 2024. Varigheten til første transje av 2024-programmet: 8. februar til senest 5. april 2024. Ytterligere informasjon om transjen kan finnes i børsmelding om dens oppstart datert 7. februar 2024, tilgjengelig her: https://newsweb.oslobors.no/search?issuer=1309 Fra 11. mars til 15. mars 2024, har Equinor ASA kjøpt tilbake totalt 1.845.000 egne aksjer til en gjennomsnittspris på NOK 272,4554 pr. aksje. Oversikt over transaksjoner: DatoHandels- plattformAggregert daglig volum (antall aksjer)Vektet gjennomsnittspris pr. aksje (NOK)Total transaksjonsverdi (NOK)11. marsOSE418.253270,5620113.163.368,20CEUX43.398271,319511.774.725,20TQEX13.349271,11583.619.124,7512. marsOSE460.000271,2967124.796.463,00CEUXTQEX13. marsOSE340.002272,555792.669.498,05CEUX74.4012

Aegon calls EUR 700 million of fixed-to-floating subordinated notes19.3.2024 08:00:00 CET | Press release

The Hague, March 19, 2024 - Aegon today announces it is exercising its right to redeem EUR 700 million of 4% fixed-to-floating subordinated notes. The redemption of these grandfathered Tier 2 securities will be effective as of April 25, 2024, when the aggregate principal amount of EUR 700 million will be repaid, together with any accrued and unpaid interest. As previously announced, Aegon intends to refinance the notes. The securities (ISIN code: XS1061711575) are currently listed on Euronext Amsterdam. This listing will be terminated following the redemption of the securities. A notice of redemption will be sent to all currently registered holders of the notes by the fiscal agent, Citibank N.A., London Branch. Contacts Media relationsInvestor relationsRichard MackillicanYves Cormier+31(0) 62 741 1546+31(0) 70 344 8028richard.mackillican@aegon.comyves.cormier@aegon.com About Aegon Aegon is an international financial services holding company. Aegon’s ambition is to build leading busines

Mendus to present NK cell program progress at the Innate Killer Summit19.3.2024 08:00:00 CET | Press release

Press Release Stockholm, Sweden, March 19, 2024 Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, announces that it will present the progress of its NK cell program at the 9th Annual Innate Killer Cell Summit, a leading conference for NK cell-based therapies. Mendus Director of Research Satwinder Kaur Singh, PhD will be expert speaker at the 9th Annual Innate Killer Summit held March 18-20 in San Diego, CA, USA. The Innate Killer Summit is a leading global conference dedicated to advancing NK cell therapies to clinic. This year’s theme of the conference is “Improve Functionality & Streamlining Manufacture to Realise the Potential of NK Therapies.” Dr Singh will present research data demonstrating the use of Mendus’ DCOne platform to expand so-called memory NK cells, their phenotypic and functional characterization and the steps taken by Mendus to develop a manufacturing process suitable for therapeutic purposes. The

Equinor ASA: Share buy-back19.3.2024 08:00:00 CET | Press release

Please see below information about transactions made under the first tranche of the 2024 share buy-back programme for Equinor ASA (OSE:EQNR, NYSE:EQNR, CEUX:EQNRO, TQEX:EQNRO). Date on which the first tranche of the 2024 programme was announced: 7 February 2024. The duration of the first tranche of the 2024 programme: 8 February to no later than 5 April 2024. Further information on the tranche can be found in the stock market announcement on its commencement dated 7 February 2024, available here: https://newsweb.oslobors.no/search?issuer=1309 From 11 March to 15 March 2024, Equinor ASA has purchased a total of 1,845,000 own shares at an average price of NOK 272.4554 per share. Overview of transactions: DateTrading venueAggregated daily volume (number of shares)Weighted average share price (NOK)Total transaction value (NOK)11 MarchOSE418,253270.5620113,163,368.20CEUX43,398271.319511,774,725.20TQEX13,349271.11583,619,124.7512 MarchOSE460,000271.2967124,796,463.00CEUXTQEX13 MarchOSE340,00

Resignation of a member of the Management Board of AB Akola Group19.3.2024 08:00:00 CET | Press release

AB Akola Group (further - the Company) hereby informs having received a notification of resignation of Dainius Pilkauskas from the position of a Member of the Board of Directors of the Company as from 30 April 2024. As of 30 April, Dainius Pilkauskas will also step down from his position as Trade Director for the Baltic States at subsidiary AB Linas Agro and, since then, will work as a consultant for Akola Group on grain trading issues. "Dainius and I have been working together successfully since 1991, and he has been the main driver of our group's international trade throughout that time. His product portfolio, especially in the early days of the Company, was diversified, but for the last couple of decades Dainius has specialised in Lithuanian and Latvian grain exports - his experience in this field is immense. I am extremely grateful to Dainius for the way we have come together, for his work on the Board, and I am delighted that he will continue to serve on the Board for almost anoth

HiddenA line styled icon from Orion Icon Library.Eye